Podcast appearances and mentions of laura niklason

Can you make lungs out of stem cells? Guest: Dr. Laura Niklason, Professor at Yale University in Anesthesia and Biomedical Engineering Learn more about your ad choices. Visit megaphone.fm/adchoices

Will BC's new short-term rental registry improve housing? Guest: Ravi Kahlon, Minister of Housing and Municipal Affairs How a 1743 study may have inspired modern day scurvy treatment Guest: Dr. Max Cooper, Senior Lecturer in Primary Care and Public Health at Brighton and Sussex Medical School Can you make lungs out of stem cells? Guest: Dr. Laura Niklason, Professor at Yale University in Anesthesia and Biomedical Engineering  Human smugglers in Canada are advertising on social media Guest: Erin Corcoran, Executive Director, Keough School of Global Affairs, University of Notre Dame CKNW is moving! Guest: Kathryn Stewart, Director of Talk and Talent at CKNW How a stage 4 cancer patient wants cancer care to improve in BC Guest: Katie Hulan, Stage Four Cancer Patient Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we talk with Dr. Laura Niklason from Yale University about her unique experiences as a PI. This podcast is a production of the NAVBO's education committee

Human Acellular Vessels are bioengineered blood conduits which have shown great promise in clinical trials for vascular applications, including arteriovenous access for hemodialysis, peripheral arterial disease, and trauma repair. Dr. Laura Niklason, Founder and CEO of Humacyte, discusses this promising technology and its recent deployment as humanitarian aid for repairing vascular trauma in Ukraine.

Humacyte's human acellular vessels are experimental, engineered, off-the-shelf replacement vessels that are being developed for vascular repair, reconstruction, and replacement. The vessels are designed to overcome long-standing limitations in vessel tissue repair and replacement. Though not yet approved, the manufactured vessels are getting a real-world test as the company has been providing them to hospitals in Ukraine to treat wounded civilians and soldiers with vascular injuries. We spoke to Laura Niklason, CEO of Humacyte, about the company's human acellular vessels, how they are produced, and the potential needs they can address.

How are stem cells being used in regenerative medicine? Adam Engler, PhD, Sharon Gerecht, PhD, Laura Niklason, MD, PhD, and Jordan Miller, PhD, explain the promising research as well as the challenges. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37555]

How are stem cells being used in regenerative medicine? Adam Engler, PhD, Sharon Gerecht, PhD, Laura Niklason, MD, PhD, and Jordan Miller, PhD, explain the promising research as well as the challenges. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37555]

How are stem cells being used in regenerative medicine? Adam Engler, PhD, Sharon Gerecht, PhD, Laura Niklason, MD, PhD, and Jordan Miller, PhD, explain the promising research as well as the challenges. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37555]

How are stem cells being used in regenerative medicine? Adam Engler, PhD, Sharon Gerecht, PhD, Laura Niklason, MD, PhD, and Jordan Miller, PhD, explain the promising research as well as the challenges. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37555]

How are stem cells being used in regenerative medicine? Adam Engler, PhD, Sharon Gerecht, PhD, Laura Niklason, MD, PhD, and Jordan Miller, PhD, explain the promising research as well as the challenges. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37555]

How are stem cells being used in regenerative medicine? Adam Engler, PhD, Sharon Gerecht, PhD, Laura Niklason, MD, PhD, and Jordan Miller, PhD, explain the promising research as well as the challenges. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37555]

How are stem cells being used in regenerative medicine? Adam Engler, PhD, Sharon Gerecht, PhD, Laura Niklason, MD, PhD, and Jordan Miller, PhD, explain the promising research as well as the challenges. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37555]

A physician-scientist, her groundbreaking work in vascular and lung engineering has made Dr. Niklason a world leader in regenerative medicine. She is a member of the National Academies of Engineering and Medicine. Dr. Niklason is the founder of Humacyte and has served as President and Chief Executive Officer since November 2020 and as a member of the Humacyte Board since 2004. Dr. Niklason holds a Ph.D. in Biophysics from the University of Chicago and an M.D. from the University of Michigan.

What are the obstacles that stand between us and engineering functional lungs? Laura Niklason, MD, PhD outline the promises and challenges of lung regeneration. She details current studies that may unveil a roadmap for building functional lung aveolus. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37580]

What are the obstacles that stand between us and engineering functional lungs? Laura Niklason, MD, PhD outline the promises and challenges of lung regeneration. She details current studies that may unveil a roadmap for building functional lung aveolus. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37580]

What are the obstacles that stand between us and engineering functional lungs? Laura Niklason, MD, PhD outline the promises and challenges of lung regeneration. She details current studies that may unveil a roadmap for building functional lung aveolus. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37580]

What are the obstacles that stand between us and engineering functional lungs? Laura Niklason, MD, PhD outline the promises and challenges of lung regeneration. She details current studies that may unveil a roadmap for building functional lung aveolus. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37580]

What are the obstacles that stand between us and engineering functional lungs? Laura Niklason, MD, PhD outline the promises and challenges of lung regeneration. She details current studies that may unveil a roadmap for building functional lung aveolus. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37580]

What are the obstacles that stand between us and engineering functional lungs? Laura Niklason, MD, PhD outline the promises and challenges of lung regeneration. She details current studies that may unveil a roadmap for building functional lung aveolus. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37580]

What are the obstacles that stand between us and engineering functional lungs? Laura Niklason, MD, PhD outline the promises and challenges of lung regeneration. She details current studies that may unveil a roadmap for building functional lung aveolus. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37580]

In this episode of SPAC #Edge, Mark Yusko speaks to a SPAC sponsor and the CEO of a company that went public via a SPAC. Laura Niklason, MD., PhD., founder and CEO of Humacyte, a clinical-stage biotechnology platform company, and Rajiv Shukla, CEO of Alpha Healthcare Acquisition Corp, provide their unique perspective of the SPAC process from each side of the SPAC structure. Humacyte, a first-in-class business and the ideal type of business for a SPAC, recently completed a merger with Alpha HealthCare's SPAC.   You'll hear about their experience around the SPAC merger process and how science fiction, in their experience, truly became science fact.   To learn more about SPACs, Morgan Creek, and the investment solutions we offer, visit us on the web at https://www.morgancreekcap.com or contact us at IR@morgancreekcap.com.

A company with roots in a Duke University lab is developing implantable human tissue right here in Research Triangle Park. Humacyte is led by co-founder and chief executive Dr. Laura Niklason, who says this is a first-of-its kind breakthrough that could save thousands of limbs from amputation, improve care for patients on hemodialysis, and more. Host Jason deBruyn explains the potential health breakthrough and talks with Niklason about the company's history and future.

Dr. Laura Niklason, co-founder of Humacyte, joins Field Notes to discuss the exciting potential of her company's human acellular vessel, which could transform vascular access for dialysis patients